Skip to content

Clinical trials

Phase 3 Blast Crisis trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Blast Crisis Phase: Phase 3 Country / region: United States Clear all

21 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20003
20011
20022
20041
20051
20061
20071
20085

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed18
Terminated2
Unknown status1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Fred Hutchinson Cancer Center3
Memorial Sloan Kettering Cancer Center3
Alliance for Clinical Trials in Oncology2
Jonsson Comprehensive Cancer Center2
Vanderbilt-Ingram Cancer Center2
Case Comprehensive Cancer Center1
European Organisation for Research and Treatment of Cancer - EORTC1
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium1
INSYS Therapeutics Inc1
Martin, Paul1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Blast Crisis21
Precursor Cell Lymphoblastic Leukemia-Lymphoma21
Burkitt Lymphoma20
Leukemia, Myeloid, Accelerated Phase20
Leukemia, Myeloid, Chronic-Phase20
Leukemia, Lymphocytic, Chronic, B-Cell19
Lymphoma, B-Cell, Marginal Zone19
Lymphoma, Follicular19
Lymphoma, Large B-Cell, Diffuse19
Lymphoma, Large-Cell, Immunoblastic19

Trials

Showing 1 to 21 of 21. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.